RhumbLine Advisers
NUVB icon

RhumbLine Advisers’s Nuvation Bio NUVB Stock Holding History

RhumbLine Advisers’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.8M Buy
316,566
+12,685
+4% +$62K ﹤0.01% 1991
2026
Q1 		$1.3M Sell
303,881
-4,308
-1% -$24K ﹤0.01% 2064
2025
Q4 		$2.76M Sell
308,189
-1,997
-0.6% -$12.4K ﹤0.01% 1698
2025
Q3 		$1.15M Buy
310,186
+12,700
+4% +$34.6K ﹤0.01% 2170
2025
Q2 		$580K Buy
297,486
+47,561
+19% +$99.1K ﹤0.01% 2595
2025
Q1 		$440K Sell
249,925
-13,880
-5% -$31.6K ﹤0.01% 2654
2024
Q4 		$702K Sell
263,805
-2,578
-1% -$6.64K ﹤0.01% 2453
2024
Q3 		$610K Buy
266,383
+5,444
+2% +$16.6K ﹤0.01% 2570
2024
Q2 		$762K Buy
260,939
+53,389
+26% +$163K ﹤0.01% 2394
2024
Q1 		$755K Sell
207,550
-2,747
-1% -$5.28K ﹤0.01% 2417
2023
Q4 		$318K Sell
210,297
-3,949
-2% -$5.08K ﹤0.01% 2935
2023
Q3 		$287K Sell
214,246
-185,963
-46% -$310K ﹤0.01% 2954
2023
Q2 		$720K Buy
400,209
+228,478
+133% +$388K ﹤0.01% 2468
2023
Q1 		$285K Sell
171,731
-2,598
-1% -$5.27K ﹤0.01% 2631
2022
Q4 		$335K Buy
174,329
+2,499
+1% +$5.06K ﹤0.01% 2635
2022
Q3 		$385K Buy
171,830
+9,431
+6% +$26.9K ﹤0.01% 2615
2022
Q2 		$526K Sell
162,399
-252
-0.2% -$1.1K ﹤0.01% 2478
2022
Q1 		$856K Buy
162,651
+12,174
+8% +$68.4K ﹤0.01% 2192
2021
Q4 		$1.28M Buy
150,477
+98,100
+187% +$902K ﹤0.01% 2107
2021
Q3 		$521K Buy
52,377
+17,730
+51% +$161K ﹤0.01% 2523
2021
Q2 		$323K Buy
+34,647
New +$395K ﹤0.01% 2758

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

RhumbLine Advisers's NUVB Position: Q2 2026 in Review

RhumbLine Advisers increased its Nuvation Bio (NUVB) stake by 4.2% in Q2 2026, buying an estimated $62K and bringing the position to 316,566 shares worth $1.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1991.

RhumbLine Advisers first reported a position in NUVB in Q2 2021 and has held it in 21 quarters since. The position peaked at $2.76M in Q4 2025. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • RhumbLine Advisers held 316,566 shares of Nuvation Bio worth $1.8M as of Q2 2026.
  • RhumbLine Advisers bought 12,685 Nuvation Bio shares in Q2 2026, an estimated $62K.
  • Nuvation Bio made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1991 holding.
  • RhumbLine Advisers first reported a position in Nuvation Bio in Q2 2021 and has held it in 21 quarters since.
  • RhumbLine Advisers's Nuvation Bio position peaked at $2.76M in Q4 2025.
  • 244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.